119-HR5467
PAAT Act
Last action was on 9-18-2025
SenateCurrent status is Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View Official Bill Information at congress.govNo users have voted for/against support on this bill yet. Be the first!
119th CONGRESS
1st Session
H. R. 5467
1. Short title2. Requiring coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D1. Short title
This Act may be cited as the "Patient Access to Autoimmune Treatments Act" or the "PAAT Act".
2. Requiring coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D
Section 1860D–4 of the Social Security Act (42 U.S.C. 1395w–104) is amended—
(1) Required inclusion of certain drugs for autoimmune diseases and blood disorders - in subsection (b)(3), by adding at the end the following new subparagraph:
(J) Required inclusion of certain drugs for autoimmune diseases and blood disorders -
(i) In general - For 2027 and each subsequent year, a PDP sponsor offering a prescription drug plan shall include each covered part D drug that is an autoimmune or blood disorder drug described in .
(ii) Autoimmune or blood disorder drug - For purposes of , a drug described in this clause is a covered part D drug indicated and prescribed for the treatment of an autoimmune disease, hemophilia, or Von Willebrand disease.
(2) Prohibition on use of prior authorization for certain autoimmune or blood disorder drugs - in subsection (c)—
(A) - by redesignating paragraph (6), as added by section 50354 of division E of the Bipartisan Budget Act of 2018 (Public Law 115–123), as paragraph (7); and
(B) Prohibition on use of prior authorization for certain autoimmune or blood disorder drugs - by adding at the end the following new paragraph:
(8) Prohibition on use of prior authorization for certain autoimmune or blood disorder drugs - For plan years beginning on or after January 1, 2027, a PDP sponsor offering a prescription drug plan (and an MA organization offering an MA–PD plan) may not require, with respect to an individual enrolled under such plan, that prior authorization for an autoimmune or blood disorder drug (as described in subsection (b)(3)(J)(ii)) be obtained more than once during any 12-month period unless such drug is—
(A) - typically used for a period of 12 months or less;
(B) - an opioid, a benzodiazepine, a barbiturate, or carisoprodol; or
(C) - a drug with respect to which a risk evaluation and mitigation strategy is required under Section 505–1 of the Federal Food, Drug, and Cosmetic Act.